(Q35159089)

6 August 2017

1 reference

title

Poxviruses as vaccine vectors (English)

1 reference

6 August 2017

1

Pastoret PP

1 reference

6 August 2017

Vanderplasschen A

2

1 reference

6 August 2017

publication date

1 October 2003

1 reference

Comparative Immunology, Microbiology & Infectious Diseases

6 August 2017

published in

1 reference

6 August 2017

volume

26

1 reference

6 August 2017

issue

5-6

1 reference

6 August 2017

page(s)

343-355

1 reference

Bioterrorism: what can we do?

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Applications of pox virus vectors to vaccination: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Human cowpox 1969-93: a review based on 54 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Monkeypoxvirus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

The complete DNA sequence of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Genes of variola and vaccinia viruses necessary to overcome the host protective mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Comparison of the genetic maps of variola and vaccinia viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

The Development of a Stable Smallpox Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Deletion of 55 open reading frames from the termini of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Recombinant vaccinia virus: immunization against multiple pathogens

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Bioterrorism. Smallpox vaccinations: how much protection remains?

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Risks of smallpox vaccination complications in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Complications of smallpox vaccination, 1968.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Expression of rabies virus glycoprotein from a recombinant vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

A mechanism for the inhibition of fever by a virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

NYVAC: a highly attenuated strain of vaccinia virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Nonreplicating vaccinia vector efficiently expresses recombinant genes

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Use of recombinant vaccinia-rabies glycoprotein virus for oral vaccination of wildlife against rabies: innocuity to several non-target bait consuming species

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Human infection due to recombinant vaccinia-rabies glycoprotein virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

High-frequency homologous recombination in vaccinia virus DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Recombinants between vaccinia and ectromelia viruses bearing the specific pathogenicity markers of both parents

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Comparison of the susceptibility of the red fox (Vulpes vulpes) to a vaccinia-rabies recombinant virus and to cowpox virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Primary multiplication site of the vaccinia-rabies glycoprotein recombinant virus administered to foxes by the oral route

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Fowlpox virus as a vector in non-avian species

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Efficacy studies on a canarypox-rabies recombinant virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Myxoma virus as a vaccine vector for rabbits: antibody levels to influenza virus haemagglutinin presented by a recombinant myxoma virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Swinepox virus as a vaccine vector for swine pathogens.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxvirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Oral vaccination of the fox against rabies using a live recombinant vaccinia virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

First field trial of fox vaccination against rabies using a vaccinia-rabies recombinant virus

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

Large-scale eradication of rabies using recombinant vaccinia-rabies vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0147-9571%2803%2900019-5

7 January 2021

10.1016/S0147-9571(03)00019-5

Identifiers

DOI

1 reference

6 August 2017

1 reference